Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 18;9(9):CD000279.
doi: 10.1002/14651858.CD000279.pub4.

Strategies for detecting colon cancer in patients with inflammatory bowel disease

William A Bye  1 , Tran M Nguyen, Claire E Parker, Vipul Jairath, James E East
Affiliations

Strategies for detecting colon cancer in patients with inflammatory bowel disease

William A Bye et al. Cochrane Database Syst Rev. .

Abstract

Background: Patients with longstanding ulcerative colitis and colonic Crohn's disease have an increased risk of colorectal cancer (CRC) compared with the general population. This review assessed the evidence that endoscopic surveillance may prolong life by allowing earlier detection of CRC or its pre-cursor lesion, dysplasia, in patients with inflammatory bowel disease (IBD).

Objectives: To assess the effectiveness of cancer surveillance programs for diagnosis of IBD-associated colorectal cancer and in reducing the mortality rate from colorectal cancer in patients with IBD.

Search methods: We searched MEDLINE, EMBASE, CENTRAL and clinical clinicaltrials.gov from inception to 19 September 2016. We also searched conference abstracts and reference lists to identify additional studies.

Selection criteria: Potentially relevant articles were reviewed independently and unblinded by two authors to determine eligibility. Randomised controlled trials (RCTs) or observational studies (cohort or case control) assessing any form of endoscopic surveillance aimed at early detection of CRC were considered for inclusion. Studies had to have a no surveillance comparison group to be eligible for inclusion.

Data collection and analysis: Eligible studies were reviewed in duplicate and the results of the primary research trials were independently extracted by two authors. The primary outcome was detection of CRC. Secondary outcomes included death from CRC, time to cancer detection, time to death and adverse events. Deaths from CRC were derived from life tables, survival curves or where possible, by calculating life tables from the data provided. The presence of significant heterogeneity among studies was tested by the chi-square test. Because this is a relatively insensitive test, a P value of less than 0.1 was considered statistically significant. Provided statistical heterogeneity was not present, the fixed effects model was used for the pooling of data. The 2x2 tables were combined into a summary test statistic using the pooled odds ratio (OR) and 95% confidence intervals as described by Cochrane and Mantel and Haenszel. The methodological quality of the included studies was assessed using the Newcastle-Ottawa scale for non-randomised studies The overall quality of the evidence supporting the primary and selected secondary outcomes was assessed using the GRADE criteria.

Main results: No RCTs were identified. Five observational studies (N = 7199) met the inclusion criteria. The studies scored well on the Newcastle-Ottawa scale, but due to the nature of observational studies, a high risk of bias was assigned to all the studies. Three studies were pooled to assess the rate of cancer detected in the surveillance group compared to the non-surveillance group. The studies found a significantly higher rate of cancer detection in the non surveillance group compared to the surveillance group. CRC was detected in 1.83% (53/2895) of patients in the surveillance group compared to 3.17% (135/4256) of patients in the non-surveillance group (OR 0.58, 95% CI 0.42 to 0.80; P = 0.0009). Four studies were pooled to assess the death rate associated with CRC in patients who underwent surveillance compared to patients who did not undergo surveillance. There was a significantly lower death rate associated with CRC in the surveillance group compared to the non-surveillance group. Eight per cent (15/176) of patients in the surveillance group died from CRC compared to 22% (79/354) of patients in the non-surveillance group (OR 0.36, 95% CI 0.19 to 0.69, P=0.002). Data were pooled from two studies to examine the rate of early stage versus late stage colorectal cancer (Duke stages A & B compared to Duke stages C & D) in patients who underwent surveillance compared to patients who do not undergo surveillance. A significantly higher rate of early stage CRC (Duke A & B) was detected in the surveillance group compared to the non-surveillance group. Sixteen per cent (17/110) of patients in the surveillance group had early stage CRC compared to 8% (9/117) of patients in the non-surveillance group (OR 5.40, 95% CI 1.51 to 19.30; P = 0.009). A higher rate of late stage CRC (Duke C & D) was observed in the non-surveillance group compared to the surveillance group. Nine per cent (10/110) of patients in the surveillance group had late stage CRC compared to 16% (19/117) of patients in the non-surveillance group (OR 0.46, 95% CI 0.08 to 2.51; P = 0.37). A GRADE analysis indicated that the quality of the data was very low for all of these outcomes. The included studies did not report on the other pre-specified outcomes including time to cancer detection, time to death and adverse events.

Authors' conclusions: The current data suggest that colonoscopic surveillance in IBD may reduce the development of both CRC and the rate of CRC-associated death through early detection, although the quality of the evidence is very low. The detection of earlier stage CRC in the surveillance group may explain some of the survival benefit observed. RCTs assessing the efficacy of endoscopic surveillance in people with IBD are unlikely to be undertaken due to ethical considerations.

PubMed Disclaimer

Conflict of interest statement

William Bye‐No known conflicts of interest

Tran Nguyen‐ No known conflicts of interest

James East‐ Clinical advisory boards: Lumendi, Boston Scientific.

Vipul Jairath‐ has received scientific advisory board fees from AbbVie, Sandoz, Takeda, Janssen; speaker’s fees from Takeda, Janssen, Shire, Ferring

Claire Parker‐ No known conflicts of interest

Figures

1
1
Study flow diagram.
1.1
1.1. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 1 Cancer detection.
1.2
1.2. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 2 Death from colorectal cancer.
1.3
1.3. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 3 Cancer Stage‐ Duke A.
1.4
1.4. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 4 Cancer Stage‐ Duke B.
1.5
1.5. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 5 Cancer stage‐ Duke C.
1.6
1.6. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 6 Cancer stage‐ Duke D.
1.7
1.7. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 7 Cancer stage‐ Duke A or B.
1.8
1.8. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 8 Cancer stage‐ Duke C or D.
1.9
1.9. Analysis
Comparison 1 Surveillance versus non surveillance, Outcome 9 Colectomy.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Ananthakrishnan 2014 {published data only}
    1. Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clinical Gastroenterology & Hepatology 2015;13(2):322‐9. - PMC - PubMed
    1. Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, et al. Colonoscopy is associated with a reduced risk of colon cancer and morality in patients with inflammatory bowel diseases. American Journal of Gastroenterology 2014;109:S639. - PMC - PubMed
Choi 1993 {published data only}
    1. Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105:418‐24. - PubMed
Karlen 1998a {published data only}
    1. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998;42:711‐4. - PMC - PubMed
Lashner 1990 {published data only}
    1. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: Historical cohort study. American Journal of Gastroenterology 1990;85(9):1083‐7. - PubMed
Lutgens 2009 {published data only}
    1. Lutgens MW, Oldenburg B, Siersema PD, Bodegraven AA, Dijkstra G, Hommes DW, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. British Journal of Cancer 2009;101(10):1671‐5. - PMC - PubMed
    1. Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, Woude CJ, Hommes DW, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008;57(9):1246‐51. - PubMed

References to studies excluded from this review

Akbar 2015 {published data only}
    1. Akbar T, Rahmany S, Harris R, Cotton S, McCabe LA, Lloyd DA, et al. Colorectal cancer in inflammatory bowel disease‐is surveillance working?. United European Gastroenterology Journal 2015;1:A626.
Arthurs 2012 {published data only}
    1. Arthurs E, Burley K, Gholkar B, Williams L, Lockett M. Colorectal cancer surveillance in inflammatory bowel disease: A retrospective audit of primary and secondary care. Journal of Crohn's and Colitis 2012;6:S139.
Basseri 2012 {published data only}
    1. Basseri RJ, Basseri B, Vassilaki ME, Melmed GY, Ippoliti A, Vasiliauskas EA, et al. Colorectal cancer screening and surveillance in Crohn's colitis. Journal of Crohn's and Colitis 2012;6(8):824‐9. - PubMed
Biasco 2002 {published data only}
    1. Biasco G, Rossini FP, Hakim R, Brandi G, Battista M, Febo G, et al. Cancer surveillance in ulcerative colitis: critical analysis of long‐term prospective programme. Digestive and Liver Disease 2002;34(5):339‐42. - PubMed
Bopanna 2016 {published data only}
    1. Bopanna S, Das P, Dattagupta S, Pratap Mouli V, Kedia S, Dhingra R, et al. High incidence of ulcerative colitis related colorectal cancer in a low incidence area of sporadic colon cancer. Gastroenterology 2016;1:S765.
Brostrom 1986 {published data only}
    1. Brostrom O, Lofberg R, Ost A, Reichard H. Cancer surveillance of patients with longstanding ulcerative colitis: A clinical, endoscopical, and histological study. Gut 1986;27(12):1408‐13. - PMC - PubMed
Carballal 2014 {published data only}
    1. Carballal S, Lopez‐Ceron M, Ricart E, Miguel CR, Cuatrecasas M, Romero I, et al. Results of a chromoendoscopy‐based surveillance program for long‐standing colonic inflammatory bowel disease. Gastrointestinal Endoscopy 2014;1:AB464.
Choi 2015 {published data only}
    1. Choi CH, Rutter M, Askari A, Lee GH, Warusavitarne J, Moorghen M, et al. Forty‐year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: An updated overview. American Journal of Gastroenterology 2015;110:1022‐34. - PMC - PubMed
Eaden 2000 {published data only}
    1. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case‐control study. Alimentary Pharmacology & Therapeutics 2000;14:145‐53. - PubMed
Friedman 2001 {published data only}
    1. Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820‐6. - PubMed
Gonzalez 2016 {published data only}
    1. Gonzalez R, Pereyra L, Gomez EJ, Mella JM, Omodeno M, Panigadi N, et al. Neoplasia Detection During Colonoscopic Surveillance of Patients With Inflammatory Bowel Disease: Does the Endoscopist's and Endoscopie's Characteristics Matter?. Gastrointestinal Endoscopy 2016;1:AB291.
Gunther 2011 {published data only}
    1. Gunther U, Kusch D, Heller F, Burgel N, Leonhardt S, Daum S, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: Comparison of random biopsy vs. targeted biopsy protocols. International Journal of Colorectal Disease 2011;26(5):667‐72. - PubMed
Hata 2003 {published data only}
    1. Hata K, Watanabe T, Kazama S, Suzuki K, Shinozaki M, Yokoyama T, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23‐year surveillance programme in the Japanese population. British Journal of Cancer 2003;89(7):1232‐6. - PMC - PubMed
Hernandez 2013 {published data only}
    1. Hernandez N, Penate M, Saiz P, Monescillo A, Jimenez E, Sanchez MA, et al. Dysplasia and colorectal cancer in surveillance colonoscopies of ulcerative colitis in a single center: Retrospective study. Journal of Crohn's and Colitis 2013;7:S112.
Higashi 2011 {published data only}
    1. Higashi D, Futami K, Ishibashi Y, Egawa Y, Maekawa T, Matsui T, et al. Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Research 2011;31(7):2499‐504. - PubMed
Hiroyuki 2014 {published data only}
    1. Hiroyuki A, Shinsuke K, Takashi N, Toshiaki T, Junichiro T, Tomomichi K, et al. Effectiveness of 34‐year surveillance colonoscopy program for long‐standing ulcerative colitis in a single institution. Inflammatory Bowel Diseases 2014;20:S42.
Jonsson 1994 {published data only}
    1. Jonsson B, Ahsgren L, Andersson LO, Stenling R, Rutegard J. Colorectal cancer surveillance in patients with ulcerative colitis. British Journal of Surgery 1994;81:689‐91. - PubMed
Lindberg 2005 {published data only}
    1. Lindberg B, Persson B, Veress B, Ingelman‐Sundberg H, Granqvist S. Efficiency of colorectal cancer surveillance in patients with ulcerative colitis: 26 Years' experience in a patient cohort from a defined population area. Scandinavian Journal of Gastroenterology 2005;40(9):1076‐80. - PubMed
Lofberg 1990 {published data only}
    1. Lofberg R, Brostrom O, Karlen P, Tribukait B, Ost A. Colonoscopic surveillance in long‐standing total ulcerative colitis ‐ a 15‐year follow‐up study. Gastroenterology 1990;99:1021‐31. - PubMed
Lynch 1993 {published data only}
    1. Lynch D, Lobo AJ, Sobala GM, Dixon MF, Axon AT. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993;34(8):1075‐80. - PMC - PubMed
Manninen 2013 {published data only}
    1. Manninen P, Karvonen AL, Huhtala H, Aitola P, Hyoty M, Nieminen I, et al. The risk of colorectal cancer in patients with inflammatory bowel disease in Finland: A follow‐up of 20 years. Journal of Crohn's and Colitis 2013;7:551‐7. - PubMed
Matsuoka 2013 {published data only}
    1. Matsuoka H, Ikeuchi H, Uchino M, Bando T, Takesue Y, Nishigami T, et al. Clinicopathological features of ulcerative colitis‐associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. International Journal of Colorectal Disease 2013;28:829‐34. - PubMed
Monzur 2013 {published data only}
    1. Monzur F, Jennings J, Mattar M, Charabaty A. IBD‐associated CRC: Are we screening often enough?. American Journal of Gastroenterology 2013;108:S501‐2.
Mooiweer 2015 {published data only}
    1. Mooiweer E, Meulen AE, Woude CJ. Incidence of interval colorectal cancer among inflammatory bowel disease patients enrolled in a colonoscopic surveillance program. Gastroenterology 2014;1:S632. - PubMed
Nugent 1991 {published data only}
    1. Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991;100:1241‐8. - PubMed
Panara 2016 {published data only}
    1. Panara AJ, Zhang HC, Waljee AK, Gaidos J, Feagins LA, Govani SM, et al. Presence of colonic dysplasia prior to colorectal cancer diagnosis is associated with early stage cancer among patients with inflammatory bowel disease: A national cohort study. Gastroenterology 2016;1:S561.
Riegler 2003 {published data only}
    1. Riegler G, Bossa F, Caserta L, Pera A, Tonelli F, Sturniolo GC, et al. Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy: A retrospective co‐operative IG‐IBD study. Digestive and Liver Disease 2003;35:628‐34. - PubMed
Rodino 2011 {published data only}
    1. Rodino S, D'Amico T, Sebkova L, Sacca N. Fifteen years colonoscopy surveillance for colorectal cancer in patients with inflammatory bowel disease: Efficacy of endoscopic polypectomy. Gastrointestinal Endoscopy 2011;1:AB439.
Rosenstock 1985 {published data only}
    1. Rosenstock E, Farmer RG, Petras R, Sivak MV Jr, Rankin GB, Sullivan BH. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985;89:1342‐6. - PubMed
Rutegard 2016 {published data only}
    1. Rutegard M, Palmqvist R, Stenling R, Lindberg J, Rutegard J. Efficiency of Colorectal Cancer Surveillance in Patients With Ulcerative Colitis: 38 Years' Experience in a Patient Cohort From a Defined Population Area. Scandinavian Journal of Surgery 2016;18:18. - PubMed
Rutter 2006 {published data only}
    1. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Thirty‐Year Analysis of a Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis. Gastroenterology 2006;130(4):1030‐8. - PubMed
Saoula 2013 {published data only}
    1. Saoula H, Boutaleb AF, Aissaoui M, Mahiou H, Salah A, Zmiri Y, et al. Screening for dysplasia and colorectal cancer in ulcerative colitis. United European Gastroenterology Journal 2013:A211.
Stolwijk 2013 {published data only}
    1. Stolwijk JAM, Langers AMJ, Hardwick JC, Veenendaal RA, Verspaget HW, Hogezand RA, et al. A thirty‐year follow‐up surveillance study for neoplasia of a Dutch ulcerative colitis cohort. Scientific World Journal 2013:Article Number: 274715. - PMC - PubMed
Velayos 2006 {published data only}
    1. Velayos F, Loftus E, Jess T, Harmsen S, Bida J, Zinsmeister A, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case‐control study. Gastroenterology 2006;130:1941‐9. - PubMed

Additional references

Askling 2001
    1. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356‐62. - PubMed
Baars 2012
    1. Baars JE, Kuipers EJ, Haastert M, Nicolai JJ, Poen AC, Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long‐term survey. Journal of Gastroenterology 2012;47:1308‐22. - PMC - PubMed
Bansal 1996
    1. Bansal P, Sonnenburg A. Risk factors of colorectal cancer in inflammatory bowel disease. American Journal of Gastroenterology 1996;91:44‐8. - PubMed
Bargen 1928
    1. Bargen JA. Chronic ulcerative colitis associated with malignant disease. Archives of Surgery 1928;17(4):561‐76. - PubMed
Beaugeri 2015
    1. Beaugeri L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. New England Journal of Medicine 2015;372(15):1441‐52. - PubMed
Blonski 2008
    1. Blonksi W, Kundu R, Lewis J, Aberra F, Osterman M, Lichtenstein GR. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?. Scandinavian Journal of Gastroenterology 2008;43:698‐703. - PubMed
Boberg 2011
    1. Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Practice & Research. Clinical Gastroenterology 2011;25(6):753‐64. - PubMed
Boonstra 2013
    1. Boonstra K, Weersma RK, Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population‐Based Epidemiology, Malignancy Risk, and Outcome of Primary Sclerosing Cholangitis. Hepatology 2013;58(6):2045‐55. - PubMed
Choi 2017
    1. Choi CR, Al BakirI, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. Nature Reviews Gastroenterology and Hepatology 2017;14(4):218‐29. - PubMed
Crohn 1920
    1. Crohn BB, Rosenburg H. The sigmoidoscopic picture of chronic ulcerative colitis (non‐specific). Amercian Journal of Medical Science 1920;170:220‐8.
Crohn 1925
    1. Crohn BB, Rosenburg H. The sigmoidoscopic picture of chronic ulcerative colitis (non‐specific). American Journal of the Medical Sciences 1925;170:220.
Eaden 2001a
    1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta‐analysis. Gut 2001;48:526‐35. - PMC - PubMed
Eaden 2001b
    1. Eaden J, Abrams K, McKay H, Denley H, Mayberry J. Inter‐observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. Journal of Pathology 2001;194:152‐7. - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Ekbom 1990a
    1. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population‐based study. New England Journal of Medicine 1990;323:1228‐33. - PubMed
Feakins 2013
    1. Feakins RM. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. Journal of Clinical Pathology 2013;66(12):1005‐26. - PubMed
Fumery 2017
    1. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients with Ulcerative Colitis with Low‐Grade Dysplasia: A systematic Review and Meta‐analysis. Clinical Gastroenterology and Hepatology 2017;15(5):665‐74. - PMC - PubMed
Goldman 1996
    1. Goldman H. Significance and detection of dysplasia in chronic colitis. Cancer 1996;789:2261‐3. - PubMed
Gupta 2007
    1. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133(4):1099‐105. - PMC - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. - PMC - PubMed
Hanauer 2006
    1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases 2006;12(5):S3‐9. - PubMed
Herrinton 2012
    1. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012;143(2):382‐9. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org..
Itzkowitz 2004
    1. Itzkowitz SH, Steven H, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. American Journal of Physiology. Gastrointestinal and Liver Physiology 2004;287(1):7‐17. - PubMed
Jess 2012
    1. Jess T, Rungoe C, Peyrin‐Biroulet L. Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta‐analysis of Population‐Based Cohort Studies. Clinical Gastroenterology and Hepatology 2012;10:639‐45. - PubMed
Kaplan 2015
    1. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology 2015;12:720‐27. - PubMed
Kisiel 2013
    1. Kisiel JB, Ahlquist DA. Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view. Therapeutic Advances in Gastroenterology 2013;6(5):371‐80. - PMC - PubMed
Laine 2015
    1. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 2015;148(3):639‐51. - PubMed
Lashner 1991
    1. Lashner BA. Colon cancer surveillance in ulcerative colitis. Seminars in Gastrointestinal Disease 1991;2:126‐31.
Lutgens 2013
    1. Lutgens MW, Oijen MG, Heijden GJ, Vleggar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta‐analysis of population‐based cohort studies. Inflammatory Bowel Diseases 2013;19(4):789‐99. - PubMed
Magro 2013
    1. Magro R, Langer C, Driessen A, Ensari K, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. Journal of Crohns and Colitis 2013;7(10):827‐51. - PubMed
Odze 2002
    1. Odze RD, Goldblum J, Noffsinger A, Alsaigh N, Rybicki LA, Fogt F. Inter‐observer variability in the diagnosis of ulcerative colitis‐associated dysplasia by telepathology. Modern Pathology 2002;15:379‐86. - PubMed
Riddell 1983
    1. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Human Pathology 1983;14:931‐68. - PubMed
Rutter 2004b
    1. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointestinal Endoscopy 2004;60(3):334‐9. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from¬www.cochrane‐handbook.org, 2011.
Shergill 2015
    1. Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in inflammatory bowel disease. Gastrointestinal Endoscopy 2015;81(5):1101‐21. - PubMed
Soderlund 2009
    1. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, et al. Decreasing time‐trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561‐7. - PubMed
Soetikno 2002
    1. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta‐analysis. Gastrointestinal Endoscopy 2002;56(1):48‐54. - PubMed
Thomas 2007
    1. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta‐analysis: cancer risk of low‐grade dysplasia in chronic ulcerative colitis. Alimentary Pharmacology & Therapeutics 2007;25(6):657‐68. - PubMed
Ullman 2011
    1. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807‐16. - PubMed
Wells 2017
    1. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta‐analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 31 Aug 2017).

References to other published versions of this review

Collins 2006
    1. Collins P, Mpofu C, Watson A, Rhodes J. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD000279.pub3] - DOI - PubMed

Publication types

LinkOut - more resources